Inhibitory mechanisms of naloxone on human platelets

Joen Rong Sheu, Yen Mei Lee, Ling Wen Lee, Hsiang Ning Luk, Mao Hsiung Yen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

1. In the present study, naloxone was tested for its antiplatelet activities in human platelet-rich plasma (PRP). In human PRP, naloxone (0.1-0.5 mmol/L) inhibited aggregation stimulated by a variety of agonists (i.e. collagen, adenosine diphosphate (ADP), U46619 and adrenaline). 2. Naloxone (0.1-0.5 mmol/L) did not significantly affect cyclic adenosine monophosphate and cGMP levels in human washed platelets, whereas naloxone (0.5 mmol/L) significantly inhibited thromboxane B2 formation stimulated by collagen (5 μg/mL) in human washed platelets. 3. Naloxone (0.5 mmol/L) significantly inhibited [3H]-inositol monophosphate formation of [3H]-myoinositol loaded platelets stimulated by collagen and U46619. Moreover naloxone did not influence the binding of 125I-triflavin to platelet membranes. Triflavin is an Arg-Gly-Asp-containing specific fibrinogen receptor antagonist. 4. Addition of naloxene (0.5 mmol/L) to platelet preparations tagged with diphenylhexatriene (DPH) resulted in a considerable decrease in relative fluorescence intensity. 5. It is suggested that the anti platelet effects of naloxone may be caused, at least partly, by the induction of conformational changes in the platelet membrane initially, followed by the inhibition of thromboxane A2 formation and phosphoinositide breakdown of platelets stimulated by agonists.

Original languageEnglish
Pages (from-to)585-591
Number of pages7
JournalClinical and Experimental Pharmacology and Physiology
Volume25
Issue number7-8
Publication statusPublished - 1998

Fingerprint

Naloxone
Blood Platelets
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Platelet-Rich Plasma
Collagen
Inositol
Fibrinogen Receptors
Diphenylhexatriene
Thromboxane B2
Thromboxane A2
Membranes
Phosphatidylinositols
Human Activities
Cyclic AMP
Adenosine Diphosphate
Epinephrine
Fluorescence

Keywords

  • Inositol monophosphate
  • Membrane fluidity
  • Naloxone
  • Platelet aggregation

ASJC Scopus subject areas

  • Physiology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Sheu, J. R., Lee, Y. M., Lee, L. W., Luk, H. N., & Yen, M. H. (1998). Inhibitory mechanisms of naloxone on human platelets. Clinical and Experimental Pharmacology and Physiology, 25(7-8), 585-591.

Inhibitory mechanisms of naloxone on human platelets. / Sheu, Joen Rong; Lee, Yen Mei; Lee, Ling Wen; Luk, Hsiang Ning; Yen, Mao Hsiung.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 25, No. 7-8, 1998, p. 585-591.

Research output: Contribution to journalArticle

Sheu, JR, Lee, YM, Lee, LW, Luk, HN & Yen, MH 1998, 'Inhibitory mechanisms of naloxone on human platelets', Clinical and Experimental Pharmacology and Physiology, vol. 25, no. 7-8, pp. 585-591.
Sheu, Joen Rong ; Lee, Yen Mei ; Lee, Ling Wen ; Luk, Hsiang Ning ; Yen, Mao Hsiung. / Inhibitory mechanisms of naloxone on human platelets. In: Clinical and Experimental Pharmacology and Physiology. 1998 ; Vol. 25, No. 7-8. pp. 585-591.
@article{dead078617584a7c9d7e1d4244e5f07f,
title = "Inhibitory mechanisms of naloxone on human platelets",
abstract = "1. In the present study, naloxone was tested for its antiplatelet activities in human platelet-rich plasma (PRP). In human PRP, naloxone (0.1-0.5 mmol/L) inhibited aggregation stimulated by a variety of agonists (i.e. collagen, adenosine diphosphate (ADP), U46619 and adrenaline). 2. Naloxone (0.1-0.5 mmol/L) did not significantly affect cyclic adenosine monophosphate and cGMP levels in human washed platelets, whereas naloxone (0.5 mmol/L) significantly inhibited thromboxane B2 formation stimulated by collagen (5 μg/mL) in human washed platelets. 3. Naloxone (0.5 mmol/L) significantly inhibited [3H]-inositol monophosphate formation of [3H]-myoinositol loaded platelets stimulated by collagen and U46619. Moreover naloxone did not influence the binding of 125I-triflavin to platelet membranes. Triflavin is an Arg-Gly-Asp-containing specific fibrinogen receptor antagonist. 4. Addition of naloxene (0.5 mmol/L) to platelet preparations tagged with diphenylhexatriene (DPH) resulted in a considerable decrease in relative fluorescence intensity. 5. It is suggested that the anti platelet effects of naloxone may be caused, at least partly, by the induction of conformational changes in the platelet membrane initially, followed by the inhibition of thromboxane A2 formation and phosphoinositide breakdown of platelets stimulated by agonists.",
keywords = "Inositol monophosphate, Membrane fluidity, Naloxone, Platelet aggregation",
author = "Sheu, {Joen Rong} and Lee, {Yen Mei} and Lee, {Ling Wen} and Luk, {Hsiang Ning} and Yen, {Mao Hsiung}",
year = "1998",
language = "English",
volume = "25",
pages = "585--591",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "7-8",

}

TY - JOUR

T1 - Inhibitory mechanisms of naloxone on human platelets

AU - Sheu, Joen Rong

AU - Lee, Yen Mei

AU - Lee, Ling Wen

AU - Luk, Hsiang Ning

AU - Yen, Mao Hsiung

PY - 1998

Y1 - 1998

N2 - 1. In the present study, naloxone was tested for its antiplatelet activities in human platelet-rich plasma (PRP). In human PRP, naloxone (0.1-0.5 mmol/L) inhibited aggregation stimulated by a variety of agonists (i.e. collagen, adenosine diphosphate (ADP), U46619 and adrenaline). 2. Naloxone (0.1-0.5 mmol/L) did not significantly affect cyclic adenosine monophosphate and cGMP levels in human washed platelets, whereas naloxone (0.5 mmol/L) significantly inhibited thromboxane B2 formation stimulated by collagen (5 μg/mL) in human washed platelets. 3. Naloxone (0.5 mmol/L) significantly inhibited [3H]-inositol monophosphate formation of [3H]-myoinositol loaded platelets stimulated by collagen and U46619. Moreover naloxone did not influence the binding of 125I-triflavin to platelet membranes. Triflavin is an Arg-Gly-Asp-containing specific fibrinogen receptor antagonist. 4. Addition of naloxene (0.5 mmol/L) to platelet preparations tagged with diphenylhexatriene (DPH) resulted in a considerable decrease in relative fluorescence intensity. 5. It is suggested that the anti platelet effects of naloxone may be caused, at least partly, by the induction of conformational changes in the platelet membrane initially, followed by the inhibition of thromboxane A2 formation and phosphoinositide breakdown of platelets stimulated by agonists.

AB - 1. In the present study, naloxone was tested for its antiplatelet activities in human platelet-rich plasma (PRP). In human PRP, naloxone (0.1-0.5 mmol/L) inhibited aggregation stimulated by a variety of agonists (i.e. collagen, adenosine diphosphate (ADP), U46619 and adrenaline). 2. Naloxone (0.1-0.5 mmol/L) did not significantly affect cyclic adenosine monophosphate and cGMP levels in human washed platelets, whereas naloxone (0.5 mmol/L) significantly inhibited thromboxane B2 formation stimulated by collagen (5 μg/mL) in human washed platelets. 3. Naloxone (0.5 mmol/L) significantly inhibited [3H]-inositol monophosphate formation of [3H]-myoinositol loaded platelets stimulated by collagen and U46619. Moreover naloxone did not influence the binding of 125I-triflavin to platelet membranes. Triflavin is an Arg-Gly-Asp-containing specific fibrinogen receptor antagonist. 4. Addition of naloxene (0.5 mmol/L) to platelet preparations tagged with diphenylhexatriene (DPH) resulted in a considerable decrease in relative fluorescence intensity. 5. It is suggested that the anti platelet effects of naloxone may be caused, at least partly, by the induction of conformational changes in the platelet membrane initially, followed by the inhibition of thromboxane A2 formation and phosphoinositide breakdown of platelets stimulated by agonists.

KW - Inositol monophosphate

KW - Membrane fluidity

KW - Naloxone

KW - Platelet aggregation

UR - http://www.scopus.com/inward/record.url?scp=0031858228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031858228&partnerID=8YFLogxK

M3 - Article

C2 - 9673433

AN - SCOPUS:0031858228

VL - 25

SP - 585

EP - 591

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 7-8

ER -